Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 16/20 | 0.66 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636423 | 1.00 | STING1 (0.66) | STING1GPR35HDAC3HDAC4HDAC1 | |
| SCHEMBL20022241 | 0.94 | STING1 (0.66) | STING1GPR35HDAC3HDAC4HDAC1 | |
| SCHEMBL20563177 | 0.89 | STING1 (0.61) | STING1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1589579 | 0.87 | STING1 (0.68) | STING1GPR35HDAC3HDAC4HDAC1 | |
| SCHEMBL20022264 | 0.86 | STING1 (0.64) | STING1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29636390 | 0.86 | STING1 (0.64) | STING1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20562443 | 0.84 | STING1 (0.53) | STING1GPR35PTPN2 | |
| SCHEMBL29975646 | 0.84 | STING1 (0.53) | STING1GPR35PTPN2 | |
| SCHEMBL20022267 | 0.83 | STING1 (0.80) | STING1 | |
| SCHEMBL29636388 | 0.83 | STING1 (0.61) | STING1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111971277-B | Benzothiophenes and related compounds as STING agonists | 默沙东有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-110036001-B | Benzo [ b ] thiophene compounds as STING agonists | 默沙东公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2022002077-A1 | ARYL AROMATIC HETEROCYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2022-01-06 | — | — | WO | disclosed |
| CN-111971277-A | Benzothiophenes and related compounds as STING agonists | 默沙东公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10793557-B2 | Sting agonist compounds | MERCK SHARP & DOHME CORP. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10793557-B2 | Sting agonist compounds | MERCK SHARP & DOHME CORP. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2019195124-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190300513-A1 | STING AGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190300513-A1 | STING AGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-10-03 | — | — | US | disclosed |
| US-10414747-B2 | Benzo[b]thiophene compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414747-B2 | Benzo[b]thiophene compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2018067423-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20180093964-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093964-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300513-A1 | STING AGONIST COMPOUNDS | STING1, CGAS, IRF3 | STING1 1/4885GPR35 250/4885HDAC3 4824/4885 |
| US-20180093964-A1 | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | STING1, IRF3, CGAS | STING1 1/4885GPR35 597/4885HDAC3 4365/4885 |
| US-10793557-B2 | Sting agonist compounds | STING1, CGAS, IRF3 | STING1 1/4885GPR35 250/4885HDAC3 4824/4885 |
| US-10414747-B2 | Benzo[b]thiophene compounds as sting agonists | STING1, IRF3, CGAS | STING1 1/4885GPR35 597/4885HDAC3 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.